Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury.
10.1007/s11596-016-1628-1
- Author:
Xin WEI
1
;
Chen-Chen HU
1
;
Ya-Li ZHANG
1
;
Shang-Long YAO
1
;
Wei-Ke MAO
2
Author Information
1. Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
2. Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. mweike@163.com.
- Publication Type:Journal Article
- Keywords:
NLRP3 inflammasome;
cerebral edema;
inflammation;
telmisartan;
traumatic brain injury
- MeSH:
Animals;
Benzimidazoles;
administration & dosage;
Benzoates;
administration & dosage;
Blood-Brain Barrier;
drug effects;
Brain Edema;
drug therapy;
genetics;
pathology;
Brain Injuries, Traumatic;
drug therapy;
genetics;
pathology;
Caspase 1;
biosynthesis;
Gene Expression Regulation;
drug effects;
Humans;
Inflammasomes;
adverse effects;
genetics;
Interleukin-18;
biosynthesis;
Interleukin-1beta;
biosynthesis;
Male;
Mice;
NLR Family, Pyrin Domain-Containing 3 Protein;
biosynthesis;
genetics;
Signal Transduction;
drug effects
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(4):576-583
- CountryChina
- Language:English
-
Abstract:
The aim of this study was to investigate the possible beneficial role of telmisartan in cerebral edema after traumatic brain injury (TBI) and the potential mechanisms related to the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain-containing 3 (NLRP3) inflammasome activation. TBI model was established by cold-induced brain injury. Male C57BL/6 mice were randomly assigned into 3, 6, 12, 24, 48 and 72 h survival groups to investigate cerebral edema development with time and received 0, 5, 10, 20 and 40 mg/kg telmisartan by oral gavage, 1 h prior to TBI to determine the efficient anti-edemic dose. The therapeutic window was identified by post-treating 30 min, 1 h, 2 h and 4 h after TBI. Blood-brain barrier (BBB) integrity, the neurological function and histological injury were assessed, at the same time, the mRNA and protein expression levels of NLRP3 inflammasome, IL-1β and IL-18 concentrations in peri-contused brain tissue were measured 24 h post TBI. The results showed that the traumatic cerebral edema occurred from 6 h, reached the peak at 24 h and recovered to the baseline 72 h after TBI. A single oral dose of 5, 10 and 20 mg/kg telmisartan could reduce cerebral edema. Post-treatment up to 2 h effectively limited the edema development. Furthermore, prophylactic administration of telmisartan markedly inhibited BBB impairment, NLRP3, apoptotic speck-containing protein (ASC) and Caspase-1 activation, as well as IL-1β and IL-18 maturation, subsequently improved the neurological outcomes. In conclusion, telmisartan can reduce traumatic cerebral edema by inhibiting the NLRP3 inflammasome-regulated IL-1β and IL-18 accumulation.
